Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer

Diagnostic Pathology

Table 2 Univariate analysis of clinical parameters and TILs for cervical cancer survival after NAC

	PFS			OS
	HR	95% CI	P	HR	95% CI	P
Intratumoral CD8 before NAC	0.823	0.381–1.779	0.620	0.721	0.268–1.936	0.516
Peritumoral CD8 before NAC	1.040	0.482–2.244	0.920	1.424	0.530–3.826	0.483
Intratumoral CD8 after NAC	0.425	0.185–0.979	0.044	0.215	0.061–0.756	0.017
Peritumoral CD8 after NAC	0.500	0.223–1.123	0.093	0.451	0.157–1.298	0.140
Intratumoral FOXP3 before NAC	1.588	0.717–3.482	0.257	1.645	0.598–4.527	0.335
Peritumoral FOXP3 before NAC	1.265	0.585–2.735	0.550	1.432	0.533–3.848	0.477
Intratumoral FOXP3 after NAC	0..983	0.455–2.120	0.964	1.035	0.388–2.757	0.946
Peritumoral FOXP3 after NAC	2.341	1.017–5.386	0.045	3.182	1.024–9.891	0.045
Intratumoral CD8/Peritumoral FOXP3 after NAC	0.227	0.085–0.602	0.003	0.061	0.008–0.463	0.007
OR(OR vs. Non-OR)	0.165	0.022–1.214	0.077	0.249	0.0432–1.536	0.037
Clinical response (Yes vs. No)	0.419	0.194–0.905	0.027	0.397	0.148–1.066	0.067
Lymph node metastasis(Yes vs. No)	2.308	0.970–5.493	0.059	1.903	0.614–5.902	0.265
Chemotherapy regimen(BVP vs. TP)	1.150	0.512–2.585	0.735	1.668	0.573–4.860	0.348
Histological grade (I-II vs. III)	1.016	0.401–2.574	0.973	1.668	0.579–4.803	0.343
FIGO stage (Ib2 vs. IIa)	2.183	1.011–4.710	0.047	2.888	1.074–7.767	0.036
Age (< 40 vs. > 40)	1.630	0.561–4.731	0.369	0.974	0.921–1.031	0.368

To bring more possible covariates into multivariate cox regression analysis, a p-value less than 0.1 is believed to have significant difference in this univariate regression analysis

ISSN: 1746-1596